Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-0209 + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-0209||CPI0209||EZH2 inhibitor 18||CPI-0209 is a second-generation EZH2 inhibitor, which inhibits methylation of H3K27 to decrease tumor cell proliferation (NCI Drug Dictionary).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04104776||Phase Ib/II||CPI-0209 CPI-0209 + Irinotecan||A Study of CPI-0209 in Patients With Advanced Solid Tumors||Recruiting||USA | ESP||1|